Edgewise Therapeutics
EWTX
Market cap $1.61B

15.29 USD

-0.13

0.84%

At close Jun 13, 4:00 PM EDT

After hours

15.26

-0.03

0.20%

1 day

-0.84%

5 days

-1.80%

1 month

2.69%

3 months

-39.52%

6 months

-44.64%

Year to date

-43.43%

1 year

-14.63%

5 years

-49.03%

10 years

-49.03%

About: Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.

Employees: 117

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

88% more call options, than puts

Call options by funds: $61.6M | Put options by funds: $32.7M

11% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 61

11% more funds holding in top 10

Funds holding in top 10: 9 [Q4 2024] → 10 (+1) [Q1 2025]

6.04% more ownership

Funds ownership: 104.54% [Q4 2024] → 110.57% (+6.04%) [Q1 2025]

5% less funds holding

Funds holding: 199 [Q4 2024] → 190 (-9) [Q1 2025]

12% less capital invested

Capital invested by funds: $2.64B [Q4 2024] → $2.32B (-$322M) [Q1 2025]

15% less first-time investments, than exits

New positions opened: 33 | Existing positions closed: 39

See Fund Rankings

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

8%

downside

Avg. target

$39

155%

upside

High target

$51

234%

upside

4 analyst ratings

3 positive

75%

1 neutral

25%

0 negative

0%

RBC Capital Leonid Timashev	214%upside $48	Outperform Reiterated	5 Jun 2025
Wedbush Laura Chico	181%upside $43	Outperform Maintained	21 Apr 2025
Scotiabank Louise Chen	8%downside $14	Sector Perform Downgraded	3 Apr 2025
Piper Sandler Yasmeen Rahimi	234%upside $51	Overweight Maintained	2 Apr 2025

See Analyst Rankings

Financial journalist opinion

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

BOULDER, Colo. , June 3, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Annual Goldman Sachs Global Healthcare Conference on Monday, June 9, 2025 at 3:20 pm ET.

Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference

Zacks Investment Research

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy

Edgewise Therapeutics (EWTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy

Zacks Investment Research

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to a 174.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

BOULDER, Colo. , May 14, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 20, 2025, at 9:00 am ET.

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

– Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million – – On track to report data from the Phase 2 LYNX and FOX trials of sevasemten in Duchenne muscular dystrophy (Duchenne) in the second quarter of 2025 – – Expect to report data from Part D of the Phase 2 CIRRUS-HCM trial in the second half of 2025 – BOULDER, Colo. , May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent business highlights.

Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

The Motley Fool

Why Edgewise Therapeutics Stock Popped This Week

On Thursday, an analyst launched coverage of Edgewise Therapeutics (EWTX 1.56%) stock, and the market took notice in a good way. On the back of his bullish view of the company, according to data compiled by S&P Global Market Intelligence, its share price vaulted nearly 14% higher across the week.

Why Edgewise Therapeutics Stock Popped This Week

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q2

24/7 Wall Street

These 5 Insiders Are Buying During Market Chaos

Market volatility has spiked since the beginning of April, due largely to uncertainty about inflation, interest rates, upcoming quarterly reports, and mostly the impact of tariffs and a global trade war on the U.S.

These 5 Insiders Are Buying During Market Chaos

Zacks Investment Research

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Edgewise Therapeutics stock plunges 48% in a week following safety concerns for its investigational hypertrophic cardiomyopathy treatment candidate, EDG-7500.

EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

The global hypertrophic cardiomyopathy market is expected to reach $1.35 billion by 2031. Despite a temporary stock drop due to adverse events and a $200 million stock offering, the long-term outlook for Edgewise Therapeutics, Inc. remains positive with multiple catalysts rapidly approaching for EWTX stock. Key milestones include 12-week data from the CIRRUS-HCM study in 2H 2025 and a phase 3 study initiation in 1H 2026.

Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On

See News Rankings

Charts implemented using Lightweight Charts™